Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis
K. Roach (Leicester, United Kingdom), E. Castells (Leicester, United Kingdom), P. Tongue (Leicester, United Kingdom), G. Elliott (Leicester, United Kingdom), H. Marshall (Leicester, United Kingdom), M. Richardson (Leicester, United Kingdom), L. Chachi (Leicester, United Kingdom), S. Mason (Leicester, United Kingdom), A. Sutcliffe (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom)
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Session: Translational aspects of idiopathic pulmonary fibrosis
Session type: Poster Discussion
Number: 5376
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Roach (Leicester, United Kingdom), E. Castells (Leicester, United Kingdom), P. Tongue (Leicester, United Kingdom), G. Elliott (Leicester, United Kingdom), H. Marshall (Leicester, United Kingdom), M. Richardson (Leicester, United Kingdom), L. Chachi (Leicester, United Kingdom), S. Mason (Leicester, United Kingdom), A. Sutcliffe (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom). Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis. 5376
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: